|Table of Contents|

Research progress in the treatment of graft versus host disease and transplant-related liver injury

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
1138-1141
Research Field:
Publishing date:

Info

Title:
Research progress in the treatment of graft versus host disease and transplant-related liver injury
Author(s):
BAI Wei; XU Mengyuan; ZHOU Jin
The First Affiliated Hospital of Harbin Medical University，Heilongjiang Harbin 150001,China.
Keywords:
allogeneic hematopoietic stem cell transplantation; GVHD treatment plan; GVHD prediction; liver complications; GVHD treatment(glucocorticoids and sirolimus)
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2022.06.040
Abstract:
Allogeneic hematopoietic stem cell transplantation makes it possible to cure malignant diseases of the blood system.However,graft versus host disease and important organ damage appearing after transplantation have become the main complications and important causes of non-recurring death after transplantation.At present,the treatment of graft versus host disease is mainly immunosuppression,but some patients have poor curative effects and may weaken the anti-leukemia effect of the graft and increase the chance of infection.For the prevention and early identification of graft versus host disease,comparison of different drug regimens,and research and treatment of liver-related injuries have become hot topics.This article reviews the prevention,prediction,and treatment of graft versus host disease,transplant-related liver injury,and the prospects for hematopoietic stem cell transplantation.

References:

［1］GATZA E,CHOI SW.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation ［J］.Int J Hematol Oncol,2015,4(3):113-126.
［2］杨茜旭,刘林,黄晓丽,等.移植后环磷酰胺预防移植物抗宿主病的研究进展［J］.西南国防医药,2018,28(10):993-995. YANG QX,LIU L,HUANG XL,et al.Research progress on cyclophosphamide prevention of graft versus host disease after transplantation ［J］.Southwest National Defence Medical Science,2018,28(10):993-995.
［3］POWLES RL,CLINK HM,SPENCE D,et al.Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation ［J］.Lancet,1980,1:327-329.
［4］YERUSHALMI R,SHEM-TOV N,DANYLESKO I,et al.The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation fromunrelated donors ［J］.Am J Hematol,2017,92(3):259-268.
［5］RUUTU T,NIHTINEN A,NIITTYVUOPIO R,et al.A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease:improved long-term survival with triple prophylaxis ［J］.Cancer,2018,124(4):727-733.
［6］TORLN J,RINGDN O,GARMING-LEGERT K,et al.A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation ［J］.Haematologica,2016,101(11):1417-1425.
［7］GUPTA A,PUNATAR S,MATHEW L,et al.Cyclosporine plus methotrexate or cyclosporine plus mycophenolate mofetil as graft versus host disease prophylaxis in acute leukemia transplant:comparison of toxicity,engraftment kinetics and transplant outcome ［J］.Indian J Hematol Blood Transfus,2016,32(3):248-256.
［8］PENACK O,MARCHETTI M,RUUTU T,et al.Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies:updated consensus recommendations of the European Society for Blood and Marrow Transplantation［J］.Lancet Haematol，2020，7(2):e157-e167.
［9］LAI YR,CHEN YH,HU DM,et al.Multicenter phase II study of a combination of cyclosporine A,methotrexate and mycophenolatemofetil for GVHD prophylaxis:results of the Chinese Bone Marrow Transplant Cooperative Group(CBMTCG) ［J］.J Hematol Oncol,2014,7:59.
［10］RUGGERI A,LABOPIN M,BACIGALUPO A,et al.Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide ［J］.Cancer,2018,124(7):1428-1437.
［11］NAKAMAE H,KOH H,KATAYAMA T,et al.HLA haploidenticalperipheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome ［J］.Exp Hematol,2015,43(11):921-929.
［12］BASHEY ASAD,ZHANG MEI-JIE,MCCURDY SHANNON R，et al.Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide［J］.J Clin Oncol,2017,35:3002-3009.
［13］SAIF MA,BORRILL R,BIGGER BW,et al.In vivo T-cell depletion using alemtuzumab in family and unrelated donor transplantation for pediatric non-malignant disease achieves engraftment with low incidence of graft vs host disease ［J］.Pediatr Transplant,2015,19(2):211-218.
［14］彭丰玲,陈林.人免疫球蛋白在造血干细胞移植中的应用研究进展［J］.现代医药卫生,2020,36(14):2195-2198. PENG FL,CHEN L.Advances in the application of human immunoglobulin in hematopoietic stem cell transplantation［J］.J Mod Med Health,2020,36(14):2195-2198.
［15］PENG Y,CHEN X,LIU Q,et al.Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10［J］.Leukemia,2015,29(3):636-646.
［16］王佃亮.脐带间充质干细胞的临床应用［J］.中国生物工程杂志,2020,40(5):125-129. WANG TL.Clinical application of umbilical cord mesenchymal stem cell［J］.China Biotechnology,2020,40(5):125-129.
［17］许慧敏,张素平,曹伟杰,等.人脐带间充质干细胞治疗难治性急性移植物抗宿主病的单臂临床研究［J］.中国组织工程研究，2021,25(31):4921-4927. XU HM,ZHANG SP,CAO WJ,et al.Single-arm clinical study of human umbilical cord mesenchymal stem cells in the treatment of refractory acute graft-versus-host disease［J］.Chinese Journal of Tissue Engineering Research,2021,25(31):4921-4927.
［18］巫丹,尹宇.人脐带间充质干细胞治疗不同疾病的研究进展 ［J］.中国比较医学杂志,2020,30(8):125-130. WU D,YIN Y.Research progress of human umbilical cord mesenchymal stem cells for treatment of various diseases［J］.Chinese Journal of Comparative Medicine,2020,30(8):125-130.
［19］ROBERT ZEISER,BRUCE R BLAZAR.Acute graft-versus-host disease:biologic process,prevention,and therapy［J］.N Engl J Med,2017,377(22):2167-2179.
［20］BETTINA P ILIOPOULOU,KATIE HSU,MAGDIEL PREZ-CRUZ,et al.Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation ［J］.Blood Adv,2019,3(21):3419-3431.
［21］THANGAVELU GOVINDARAJAN,DU JING,PAZ KATELYN G,et al.Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease［J］.Blood,2020,135:28-40.
［22］MILLER HK,BRAUN TM,STILLWELL T,et al.Infectious risk after allogeneic hematopoietic cell transplantation complicated by acute graft-versus-host disease［J］.Biol Blood Marrow Transplant,2017,23(3):522-528.
［23］ROTZ SETH J,DANDOY CHRISTOPHER E,DAVIES STELLA M.ST2 and endothelial injury as a link between GVHD and microangiopathy［J］.N Engl J Med,2017,376:1189-1190.
［24］GEORGE B MCDONALD,LAURA TABELLINI,BARRY E STORER,et al.Predictive value of clinical findings and plasma biomarkers after 14 days of prednisone treatment for acute graft-versus-host disease［J］.Biol Blood Marrow Transplant,2017,23(8):1257-1263.
［25］MAJOR-MONFRIED HANNAH,RENTERIA ANNE S,PAWARODE ATTAPHOL,et al.MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD［J］.Blood,2018,131:2846-2855.
［26］MARK T VANDER LUGT,THOMAS M BRAUN,SAMIR HANASH,et al.ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death［J］.N Engl J Med,2013,369:529-539.
［27］FERRARA JL,HARRIS AC,GREENSON JK,et al.Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease［J］.Blood,2011,118:6702-6708.
［28］SALIBA RIMA M.Mismatch in SIRPα,a regulatory protein in innate immunity,is associated with chronic GVHD in hematopoietic stem cell transplantation［J］.Blood Advances,2021,5(17):3407-3417.
［29］秦丹,王利.氟达拉滨代替环磷酰胺的移植前预处理方案对髓系白血病疗效的Meta分析［J］.现代肿瘤医学,2018,26(21):3462-3466. QIN D,WANG L.A meta-analysis of the efficacy of pretreatment with fludarabine instead of cyclophosphamide on myeloid leukemia ［J］.Modern Oncology,2018,26(21):3462-3466.
［30］潘焕玉,朱康儿,张涛,等.白消安-氟达拉滨预处理方案对异基因造血干细胞移植后肝静脉闭塞症的影响［J］.暨南大学学报(医学版),2013,34(2):195-197. PAN HY,ZHU KE,ZHANG T,et al.Effect of busulan-fludarabine pretreatment regimen on hepatic vein occlusion after allogeneic hematopoietic stem cell transplantation ［J］.Journal of Jinan University(Medical Edition),2013,34(2):195-197.
［31］PARMAR S,LIU X,NAJJAR A,et al.Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo［J］.Blood,2015,125(9):1502-1506.
［32］PIDALA JOSEPH,HAMADANI MEHDI,DAWSON PETER,et al.Randomized multicenter trial of sirolimus vs.prednisone as initial therapy for standard risk acute GVHD:BMT CTN 1501［J］.Blood,2020,135(2):97-107.
［33］PECCATORI J,FORCINA A,CLERICI D,et al.Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors ［J］.Leukemia,2015,29(2):396-405.
［34］CARPENTER PAUL A,LOGAN BRENT R,LEE STEPHANIE J,et al.A phase II/III randomized,multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-host disease:BMT CTN 0801［J］.Haematologica,2018,103:1915-1924.
［35］ALI NATASHA,ULLAH HAYAT,SHAIKH MOHAMMAD USMAN,et al.Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure［J］.Int J Hematol Oncol,2019,8:IJH21.
［36］ FRIEDRICH PAOLA,GUERRA-GARCA PILAR,STETSON ALYSSA，et al.Young female donors do not increase the risk of graft-versus-host disease or impact overall outcomes in pediatric HLA-matched sibling hematopoietic stem cell transplantation［J］.Biol Blood Marrow Transplant,2018,24:96-102.

Memo

Memo:
-
Last Update: 1900-01-01